PLURNasdaqBiological Products, (No Diagnostic Substances)US GAAP · USD

Pluri Inc.

Pluri Inc. is a biotechnology company built around a proprietary 3D cell expansion platform used to develop cell-based products and manufacturing services. Through subsidiaries and collaborations, it applies this platform across regenerative medicine, immunotherapy, cultivated food ingredients, coffee and cacao, and cell therapy CDMO services, with operations rooted in the United States, Israel, and Germany.

Kysy yhtiöstä
Liikevaihto1,0milj. USD
−24,0 %v/v
Liikevoitto (EBIT)−24,9milj. USD
−12,5 %v/v
EBIT-marginaali−2 454,5%
−794,6 %-yks.v/v
Nettotulos−23,8milj. USD
−5,5 %v/v
Vapaa kassavirta−20,2milj. USD
−2,0 %v/v

Tilikausi 2026 · muutos edellisvuodesta

Kehitys 2021–2026

−60−40−20020milj. USD2021: 0,02 milj. USD2021: EBIT −51 milj. USD20212022: 0,23 milj. USD2022: EBIT −42 milj. USD20222023: 0,29 milj. USD2023: EBIT −27 milj. USD20232024: 0,33 milj. USD2024: EBIT −22 milj. USD20242025: 1,3 milj. USD2025: EBIT −22 milj. USD20252026: 1,0 milj. USD2026: EBIT −25 milj. USD20261,0−25
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Pluri Inc.

Liiketoiminta

Osuus liikevaihdosta
Cell expansion platform0 %

Proprietary 3D technology used to expand cells at industrial scale for multiple applications.

CDMO services55 %

Process development, manufacturing, and analytical testing for cell therapy customers.

Regenerative medicine and immunotherapy15 %

Cell-based therapeutic programs and related development activities.

Cultivated food ingredients20 %

Cell-based food products and ingredients, including cultivated coffee and cacao.

AgTech collaborations10 %

Cell-based agricultural applications, including biostimulants and crop-related POCs.

Asiakkaat

Pluri sells primarily to pharmaceutical and biotech companies that need outsourced cell therapy development and manufacturing support. It also works with food-tech, agriculture, and industrial partners pursuing cultivated ingredients, biostimulants, and other cell-based applications. In addition, some programs are developed through collaborations and joint ventures rather than direct product sales.

Pharmaceutical and biotech companies

Buy cell therapy CDMO services such as process development, manufacturing, and analytical testing.

Food-tech and cultivated ingredient partners

Work with Pluri on cultivated coffee, cacao, and other cell-based food ingredients.

Agriculture and agtech partners

Use the platform for biostimulants, crop-related proof-of-concepts, and sustainable agriculture applications.

Research and collaboration partners

Participate in clinical, technical, and commercial collaborations around cell-based technologies.

Strategia

Pluri’s strategy is to monetize its cell expansion platform across multiple end markets rather than depend on a single therapeutic program. It is building revenue through CDMO services, while also advancing cultivated food, agtech, and licensing opportunities that can reuse the same core technology. Partnerships, joint ventures, and collaborations are central because they reduce the need to commercialize every application alone.

Scale CDMO servicesLyhyt aikaväli

CDMO work provides a commercial path for the platform while supporting pharma and biotech customers.

Develop cultivated food businessesKeskipitkä aikaväli

Coffee and cacao programs extend the platform into large consumer ingredient markets.

Expand platform licensing and collaborationsKeskipitkä aikaväli

Partnerships can monetize the technology without requiring full downstream commercialization.

Maantiede

Pluri is incorporated in Nevada but its operating footprint is centered in Israel, where several subsidiaries are based and where much of the platform development occurs. It also has a German subsidiary and works with customers and clinical partners in the United States, Europe, and other regulated markets. Geography matters because the business depends on cross-border R&D, manufacturing, clinical execution, and regulatory approvals.

Riskit

Pluri faces the typical risks of an early commercial biotechnology platform: long development cycles, regulatory uncertainty, and dependence on successful execution of collaborations and manufacturing programs. It also has company-specific exposure to capital needs, Nasdaq listing compliance, and the challenge of converting a broad technology platform into durable revenue streams.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Capital raising and dilution risk1Nasdaq continued listing risk2Regulatory and clinical development risk3Commercialization risk for new verticals4Manufacturing and quality risk5Cybersecurity and data loss risk6
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Capital raising and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea

    The company may need external funding to support R&D, commercialization, and operations.

    Kohdistuu: Equity holders

  2. Nasdaq continued listing riskVaikutus: KorkeaTodennäköisyys: Korkea

    Failure to meet listing standards could pressure the share price and reduce access to capital.

    Kohdistuu: Public market liquidity

  3. Regulatory and clinical development riskVaikutus: KorkeaTodennäköisyys: Korkea

    Cell therapy and related programs depend on approvals, trial execution, and compliance.

    Kohdistuu: Therapeutic pipeline

  4. Commercialization risk for new verticalsVaikutus: KeskitasoTodennäköisyys: Korkea

    Cultivated coffee, cacao, and agtech products may take time to reach scale and acceptance.

    Kohdistuu: Food and agriculture ventures

  5. Manufacturing and quality riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    The business depends on GMP-like manufacturing discipline and reproducible cell expansion.

    Kohdistuu: CDMO and product development

  6. Cybersecurity and data loss riskVaikutus: KeskitasoTodennäköisyys: Matala

    Clinical and development programs rely on sensitive data and third-party systems.

    Kohdistuu: Clinical operations

Kysy Clarifolta: Pluri Inc.

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition over time

CDMO contracts use percentage-of-completion, so estimates of labor effort drive revenue timing.

Vaikutus: Can shift revenue between periods as project estimates change

Goodwill and intangible assets

Acquisitions such as Kokomodo create goodwill and identifiable intangibles that must be tested for impairment.

Vaikutus: Potential non-cash write-downs if expected value declines

Share-based compensation

Equity awards to employees, officers, and consultants are valued using option-pricing models.

Vaikutus: Affects operating expenses and diluted share count

Foreign currency exposure and hedging

Operations and portfolio exposures span USD, Israel, Europe, and other currencies.

Vaikutus: Can create gains/losses and hedge accounting complexity

Acquisition purchase accounting

The Kokomodo transaction required allocation of purchase price to assets, liabilities, goodwill, and intangibles.

Vaikutus: Changes future amortization and impairment profile

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Calidi Biotherapeutics, Inc.

CLDWW · Biological Products, (No Diagnostic Substances)

Lunai Bioworks Inc.

LNAI · Pharmaceutical Preparations

Purple Biotech Ltd

PPBT · Pharmaceutical Preparations

Trevi Therapeutics, Inc.

TRVI · Pharmaceutical Preparations

Absci Corp

ABSI · Services-Commercial Physical & Biological Research

Sutro Biopharma, Inc

STRO · Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026

Pluri Inc. (PLUR) liikevaihto, tulos ja tunnusluvut 2026 – Clarifo